Last reviewed · How we verify
SARS-CoV-2 VLP Vaccine
At a glance
| Generic name | SARS-CoV-2 VLP Vaccine |
|---|---|
| Sponsor | Ihsan GURSEL, PhD, Prof. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of COVID-19 Vaccine (ABNCoV2) (PHASE1)
- A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (PHASE1)
- Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a (PHASE1)
- Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant (PHASE1)
- Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a (PHASE1)
- The Phase Ⅱ/Ⅲ Trial of LYB001 (PHASE2, PHASE3)
- Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine (PHASE2)
- Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |